CN115353508B - 5-吡啶-1h-吲唑类化合物、药物组合物和应用 - Google Patents

5-吡啶-1h-吲唑类化合物、药物组合物和应用 Download PDF

Info

Publication number
CN115353508B
CN115353508B CN202211018173.7A CN202211018173A CN115353508B CN 115353508 B CN115353508 B CN 115353508B CN 202211018173 A CN202211018173 A CN 202211018173A CN 115353508 B CN115353508 B CN 115353508B
Authority
CN
China
Prior art keywords
acid
compound
found
dmso
300mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211018173.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115353508A (zh
Inventor
李志裕
卞金磊
胡天星
刘迈
宋佳星
王举波
邱志霞
吴红茜
徐熙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN202211018173.7A priority Critical patent/CN115353508B/zh
Publication of CN115353508A publication Critical patent/CN115353508A/zh
Priority to AU2022475622A priority patent/AU2022475622A1/en
Priority to US18/864,008 priority patent/US20260070889A1/en
Priority to PCT/CN2022/133423 priority patent/WO2024040768A1/zh
Priority to GB2415076.5A priority patent/GB2632571A/en
Priority to CA3255205A priority patent/CA3255205A1/en
Priority to JP2024568339A priority patent/JP2025515926A/ja
Priority to KR1020247036196A priority patent/KR20250007528A/ko
Application granted granted Critical
Publication of CN115353508B publication Critical patent/CN115353508B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202211018173.7A 2022-08-24 2022-08-24 5-吡啶-1h-吲唑类化合物、药物组合物和应用 Active CN115353508B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202211018173.7A CN115353508B (zh) 2022-08-24 2022-08-24 5-吡啶-1h-吲唑类化合物、药物组合物和应用
GB2415076.5A GB2632571A (en) 2022-08-24 2022-11-22 5-pyridine-1H-indazole compound, pharmaceutical composition, and use
US18/864,008 US20260070889A1 (en) 2022-08-24 2022-11-22 5-pyridine-1h-indazole compound, pharmaceutical composition, and use
PCT/CN2022/133423 WO2024040768A1 (zh) 2022-08-24 2022-11-22 5-吡啶-1h-吲唑类化合物、药物组合物和应用
AU2022475622A AU2022475622A1 (en) 2022-08-24 2022-11-22 5-pyridine-1h-indazole compound, pharmaceutical composition, and use
CA3255205A CA3255205A1 (en) 2022-08-24 2022-11-22 COMPOSITE OF 5-PYRIDINE-1H-INDAZOLE, PHARMACEUTICAL COMPOSITION AND USE
JP2024568339A JP2025515926A (ja) 2022-08-24 2022-11-22 ５－ピリジン－１ｈ－インダゾール系化合物、医薬組成物及び使用
KR1020247036196A KR20250007528A (ko) 2022-08-24 2022-11-22 5-피리딘-1h-인다졸계 화합물, 약학적 조성물 및 응용

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211018173.7A CN115353508B (zh) 2022-08-24 2022-08-24 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Publications (2)

Publication Number Publication Date
CN115353508A CN115353508A (zh) 2022-11-18
CN115353508B true CN115353508B (zh) 2023-07-21

Family

ID=84003747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211018173.7A Active CN115353508B (zh) 2022-08-24 2022-08-24 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Country Status (8)

Country Link
US (1) US20260070889A1 (https=)
JP (1) JP2025515926A (https=)
KR (1) KR20250007528A (https=)
CN (1) CN115353508B (https=)
AU (1) AU2022475622A1 (https=)
CA (1) CA3255205A1 (https=)
GB (1) GB2632571A (https=)
WO (1) WO2024040768A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115353508B (zh) * 2022-08-24 2023-07-21 中国药科大学 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN115785071B (zh) * 2023-01-09 2024-01-26 中国药科大学 3-乙炔基-5-（1h-1,2,3-三唑-4-基）-1h-吲唑类化合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CN102595899A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
CA2819373A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
PH12017500997A1 (en) * 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2014137728A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN106032359B (zh) * 2015-03-09 2018-07-20 复旦大学 吲唑类化合物及其制备方法和用途
MX380092B (es) * 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
CN105958990B (zh) * 2016-05-24 2019-03-29 内蒙古包钢钢联股份有限公司 光电接近开关保护装置
WO2019241540A1 (en) * 2018-06-15 2019-12-19 Samumed, Llc Indazole containing macrocycles and therapeutic uses thereof
CA3118093A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
US20230000842A1 (en) * 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
WO2022012058A1 (zh) * 2020-07-16 2022-01-20 江苏凯迪恩医药科技有限公司 稠环化合物及其中间体、制备方法和应用
CN115353508B (zh) * 2022-08-24 2023-07-21 中国药科大学 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Also Published As

Publication number Publication date
KR20250007528A (ko) 2025-01-14
GB2632571A (en) 2025-02-12
JP2025515926A (ja) 2025-05-20
CN115353508A (zh) 2022-11-18
WO2024040768A1 (zh) 2024-02-29
GB202415076D0 (en) 2024-11-27
US20260070889A1 (en) 2026-03-12
CA3255205A1 (en) 2025-03-27
AU2022475622A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
CN113024544A (zh) 一种含氰基并杂环化合物及其用途
CN120757571A (zh) Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用
WO2017088723A1 (zh) 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
CN112851663B (zh) 一种并杂环化合物及其用途
CN112292374B (zh) 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途
CN115353508B (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
CN114667289B (zh) 杂芳基血浆激肽释放酶抑制剂
CN113072550B (zh) 一种高选择性成纤维细胞生长因子受体抑制剂和应用
CN102134234A (zh) 吲唑脲类化合物及其制法和药物用途
CN115304583B (zh) 靶向抑制clk2的5-吡啶-1h-吲唑类化合物及其应用
WO2005080392A1 (ja) ピラゾロキノロン誘導体およびその用途
JP2007501267A (ja) 新規イミダゾール誘導体、その製造法及びその医薬としての使用
CN117486874A (zh) 苯并杂芳环类化合物、其药物组合物及其应用
JP4733648B2 (ja) マトリックスメタロプロテイナーゼ阻害剤としての使用のためのチエノ−イミノ酸誘導体
CN113929674B (zh) 含1,4-二氢喹唑啉结构的化合物及其制备方法与应用
CN108689937A (zh) 吲唑类化合物及其在制备ido抑制剂类药物上的用途
CN113135929B (zh) 呋喃并吡啶酮酰胺化合物及其制备方法和用途
CN112778273A (zh) 环酮并吡啶酮类化合物及其制备方法和用途
CN118146197A (zh) 炔类化合物及其制备方法、药物组合物与应用
CN115368306B (zh) 含四氢异喹啉类结构的hdac抑制剂、组合物及其用途
JP4861179B2 (ja) マトリックスメタロプロテイナーゼの阻害剤として使用される二環式イミノ酸誘導体
CN115785071B (zh) 3-乙炔基-5-（1h-1,2,3-三唑-4-基）-1h-吲唑类化合物及其应用
CN115322120A (zh) 一类小分子化合物及在制备治疗dhodh介导疾病药物中的用途
CN115260195B (zh) Egfr降解剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant